Navigation Links
Study Seeks Volunteers to Measure Safety of Treatment 'Boost' for Patients with Oropharyngeal Cancer
Date:7/23/2010

GREAT NECK, N.Y., July 23 /PRNewswire-USNewswire/ -- The North Shore-LIJ Health System Department of Radiation Medicine announced today it is seeking patients with cancer of the oropharynx (back of the mouth) to participate in a Phase I clinical trial.

Subjects must be newly diagnosed and not have undergone any previous treatment. Further, their cancer must be unassociated with the human papilloma virus (HPV-negative), or, if it is HPV-positive, they must be current or former pack-a-day smokers for at least 10 years.

Patients with HPV-negative oropharyngeal cancer are not cured as frequently by standard radiation therapy (IMRT) as are patients with the HPV-positive type, according to David Schwartz, MD, vice chair of radiation medicine at the North Shore-LIJ Health System and the study's principal investigator. The hypothesis of the study is that standard radiation therapy followed by a "boost" of image-guided stereotactic radiosurgery (SRS) will achieve a better cure rate for these two groups of patients.

Patients who volunteer to participate in the study are first screened to determine whether they are eligible, after which they provide their informed consent. Treatment can then begin--six weeks of standard radiation, possibly in combination with chemotherapy, depending on the stage of the cancer. Research nurse Sara Parise, RN, BSN, coordinates the patients' treatment.

And now on to the "boost" of SRS, which is what the study is all about. A Phase I trial establishes the safety of a treatment, and so the first group of patients receives a moderate dose of SRS, only 8Gy (Gy stands for gray, a unit of energy absorbed from ionizing radiation). This is a rigorous treatment, comparable to standard doses. All Phase I trials begin with a dose of the experimental treatment that is believed to be safe, followed by very careful monitoring of the patients' reactions. If the dose of 8Gy6 is well tolerated, the next group of patients will get a dose 2Gy higher, and again the side effects will be carefully monitored. The maximum dose will be 18Gy.

"This trial is one of the very first attempts to increase cure rates for the large number of patients with HPV-unassociated oropharyngeal cancer," Dr. Schwartz stated. "SRS is a safe, highly sophisticated technique that has generated much interest for its ability to overcome resistance of tumors to radiation. We are pleased that the North Shore-LIJ Health System has the technology and the expertise to offer this trial before any other center in the metropolitan area or anywhere in the country. Our hope is that it serves as a stepping stone for expanded use of SRS as part of standard treatment for people who face this illness."

To see if you are eligible to participate in the study or to find out more, call Ms. Parise at 718-470-7190, extension 66773.

This news release was issued on behalf of Newswise(TM).  For more information, visit http://www.newswise.com.


'/>"/>
SOURCE North Shore-Long Island Jewish Health System
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Horizon Pharma, Inc. Announces Results of Phase 3 Study of LODOTRA® Demonstrate 12-Month Sustained Efficacy and Safety in Rheumatoid Arthritis
2. Lost and Found: L2FU Recovers 100% of Clinical Trial Patients for Recent Pivotal Study
3. AVAC Praises CAPRISA 004 Trial Collaborators and Participants for Historic Study - Trial Confirms Promise of ARV-Based Microbicides
4. New Study Shows Meganuclease-Driven Targeted Integration Using Cellectis bioresearchs cGPS® CHO-K1 Kit to be Highly Efficient for Drug Discovery
5. Phase 3 Open-Label Study Comparing Tapentadol Extended Release Tablets to Oxycodone Controlled Release Tablets Published by Pain Practice
6. Worlds Largest Study on Insulin Therapy Completes Recruitment With 60,000 Patients
7. Study of Long-Term Efficacy and Safety of New PyratineXR™ Moisturizing Lotion Featured in Journal of Drugs in Dermatology
8. 12-Month Study Reports 90% Success Rate for AMS MiniArc Single-Incision Sling
9. New Study Reveals Proprietary Saw Palmetto Extract (SPET-085) Supplement Can Effectively Inhibit the Enzyme Linked to Benign Prostatic Hyperplasia (BPH)
10. Dune Medical Devices Announces Positive Interim Results From EU MarginProbe™ Study Presented at German Breast Cancer Society Meeting
11. Drug Study Shows Improvement in Major Orthopedic Surgery Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... Research and Markets has announced the addition ... Industry Forecast to 2025" report to their offering. ... The Global Apheresis Equipment Market ... the next decade to reach approximately $4.5 billion by 2025.  ... for all the given segments on global as well as regional ...
(Date:2/21/2017)... 21, 2017 Centurion Medical Products, a ... care, is making a major stride in emergency ... its IRIG-8™Wound Irrigation System . ... deliver copious volumes of irrigation solution to acute ... a significant improvement to the traditional syringe with ...
(Date:2/21/2017)... Research and Markets has announced the addition of the "EEG, ... to their offering. ... report provides separate comprehensive analytics for the US, Canada ... Asia-Pacific , Latin America , and Rest ... through 2022. Also, a six-year historic analysis is provided for these markets. ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... February 22, 2017 , ... Apptricity® Corporation, ... (SCM) and spend management, today announced that Keppel Corporation has selected Apptricity Travel ... tracking. , “We are excited to announce the partnership between Keppel and ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton celebrated the ... on Feb. 21. , The celebration began with a ribbon cutting event at ... construction team and tribal leadership. , Choctaw Nation Durant Regional Medical Clinic ...
(Date:2/21/2017)... ... 2017 , ... Doctors on Liens has announced the addition of Mendonca ... to its growing network of doctors in Central and Northern California. Dr. Mendonca specializes ... as whiplash, back pain, neck pain, hip and knee pain, and headaches. Specializing ...
(Date:2/21/2017)... ... ... Ray Insurance Agencies, a Dallas area firm providing asset protection services and ... six month charity event aimed at raising local support and donations that will be ... deadliest diseases in America; more than 7.5 million people die from cancer related disorders ...
(Date:2/21/2017)... ... February 21, 2017 , ... ... the further expansion of its eHealth App xChange™, providing clinical researchers more ... Bioclinica’s extensive and growing eHealth platform. Applications that enable patient-centered clinical trials ...
Breaking Medicine News(10 mins):